Biohaven (BHVN) stock plummeted Thursday after the company paused enrollment in a midstage study of its seizure treatment opakalim due to safety concerns. The Food and Drug Administration (FDA) is now requiring Biohaven to assess the potential for human toxicity from a metabolite in the drug, which is in testing for focal onset seizures, after issues were observed in rats.